Article Text

other Versions

PDF
Original article
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel
  1. Petr Widimsky1,
  2. Zuzana Motovska1,
  3. Leonardo Bolognese2,
  4. Dariusz Dudek3,
  5. Christian Hamm4,
  6. Jean-Francois Tanguay5,
  7. Jurrien ten Berg6,
  8. Eileen Brown7,
  9. LeRoy LeNarz7,
  10. Debra L Miller7,
  11. Gilles Montalescot8,
  12. for the ACCOAST Investigators
  1. 1Cardiocenter, Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic
  2. 2Cardiovascular and Neurological Department Azienda Ospedaliera, Arezzo, Italy
  3. 3Institute of Cardiology, Jagiellonian University Medical College, University Hospital, Krakow, Poland
  4. 4Kerckhoff Heart and Thoraxcenter, Bad Nauheim and Medical Clinic I, University of Giessen Germany, Bad Nauheim, Germany
  5. 5Montreal Heart Institute, Montreal, Quebec, Canada
  6. 6Department of Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands
  7. 7Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
  8. 8Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France
  1. Correspondence to Dr Zuzana Motovska, Cardiocenter, Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic; zuzana.motovska{at}fnkv.cz

Abstract

Background When considering antiplatelet therapy for acute coronary syndrome (ACS), it is essential to balance benefits (less thrombotic/ischaemic events) versus bleeding risks related to intense platelet inhibition via antagonism of P2Y12 receptors. This analysis aimed to identify predictors of bleeding events among A Comparison of Prasugrel at the Time of PCI or as Pretreatment at the Time of Diagnosis in Patients with NSTEACS (ACCOAST) study population.

Methods and results The ACCOAST study randomised 4033 patients with non-ST-segment elevation myocardial infarction (NSTEMI) to (A) a 30 mg prasugrel loading dose (LD) followed by coronary angiography with an additional 30 mg prasugrel at the time of percutaneous coronary intervention (PCI) or (B) a placebo LD followed by a 60 mg prasugrel at the time of PCI. Patients received standard of care, including use of aspirin. Independent predictors of Thrombolysis in Myocardial Infarction (TIMI) major bleeding not related to coronary artery bypass grafting (CABG) within 7 days were assessed using stepwise Cox proportional model for time to first occurrence of the event. Non-CABG-related TIMI major or minor bleeding was similarly analysed. Non-CABG-related TIMI major bleeding occurred in 36 (0.9%) patients, and TIMI major or minor bleeding occurred in 81 (2.0%) patients. Independent predictors for TIMI major bleeding alone were pretreatment with prasugrel LD (HR 3.02; 95% CI 1.42 to 6.43), femoral access (HR 2.45; 95% CI 1.11 to 5.38), female sex (HR 2.57; 95% CI 1.32 to 5.00), placement of >1 stent (HR 2.50; 95% CI 1.26 to 4.95) and age (HR 1.05; 95% CI 1.02 to 1.09). Pretreatment with prasugrel LD (HR 3.05; 95% CI 1.84 to 5.07), femoral access (HR 3.06; 95% CI 1.74 to 5.38), female sex (HR 2.62; 95% CI 1.67 to 4.12), performed PCI (HR 2.21; 95% CI 1.23 to 3.99), therapy with glycoprotein IIb/IIIa inhibitors (HR 1.88; 95% CI 1.06 to 3.33) and age (increased bleed per year of age HR 1.04; 95% CI 1.02 to 1.06) were independent predictors of TIMI major or minor bleeding through 7 days.

Conclusions Pretreatment, age, gender and procedural variables predicted bleeding risk in patients with NSTEMI.

Clinical registration No NCT01015287.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.